References
- Gudjonsson JE, Elder JT. Psoriasis: Epidemiology. Clin Dermatol. 2007; 25:535–546.
- Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994; 96:146–151.
- Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-stoma A, Nockowski P, Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008; 394:7–21.
- Pathare SK, Heycock C, Hamilton J. TNFalpha blocker- induced thrombocytopenia. Rheumatology (Oxford). 2006; 45:1313–1314.
- Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-saab S, Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003; 71:396–398.
- Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003; 139:W–W63.
- Stinco G, Piccirillo F, Patrone P. Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis. Acta Derm Venereol. 2008; 88:281–282.
- Lahbabi I, Adamski H, Le Jean S, Cannieux V, Polard E, Chevrant-Breton J. Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept. Ann Dermatol Venereol. 2008; 135:409–410.
- Phelan C, Wooltorton E. Infliximab and serious hematologic events. CMAJ. 2004; 171:1045.